News from pivotal therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 10, 2015, 12:28 ET

Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors

WOODBRIDGE, ON, Feb. 10, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Jan 27, 2015, 13:23 ET

Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100

WOODBRIDGE, ON, Jan. 27, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Jan 22, 2015, 15:38 ET

Pivotal Therapeutics: Year in Review and CEO Update

WOODBRIDGE, ON, Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Jan 05, 2015, 17:10 ET

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

WOODBRIDGE, ON, Jan. 5, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Dec 17, 2014, 07:38 ET

Permiso para la evaluación clínica del protocolo del ensayo VASCAZEN® POMEGA Phase IIa por medio de la FDA de Francia

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" o la "compañía"), una compañía farmacéutica especializada...

Dec 17, 2014, 07:30 ET

VASCAZEN® POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA

WOODBRIDGE, ON, Dec. 17, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Nov 28, 2014, 17:22 ET

Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results

WOODBRIDGE, ON, Nov. 28, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Nov 14, 2014, 15:15 ET

Pivotal Therapeutics Announces Senior Management Change

WOODBRIDGE, ON, Nov. 14, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Oct 09, 2014, 11:40 ET

Pivotal recibe la notificación de patente de VASCAZEN® y el inhibidor de absorción de colesterol

- Pivotal recibe la notificación de permiso de patente de Estados Unidos relacionada con la combinación de VASCAZEN® y el inhibidor...

Oct 08, 2014, 12:44 ET

Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor

WOODBRIDGE, ON, Oct. 8, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Oct 07, 2014, 12:02 ET

Pivotal Therapeutics anuncia la notificación de permiso de patente para la aplicación de Estados Unidos 13/584,480

- Pivotal Therapeutics anuncia la notificación de permiso de patente para la aplicación de Estados Unidos 13/584,480 relacionada con la...

Oct 07, 2014, 07:00 ET

Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN® and Statin Therapy

WOODBRIDGE, ON, Oct. 7, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Oct 03, 2014, 14:37 ET

Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes

WOODBRIDGE, ON, Oct. 3, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Sep 15, 2014, 17:42 ET

Pivotal Therapeutics Grants Incentive Stock Options

WOODBRIDGE, ON, Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Sep 15, 2014, 02:07 ET

Pivotal anuncia un ensayo que muestra los efectos beneficiosos de VASCAZEN® para corregir la deficiencia de Omega-3

- Pivotal anuncia la publicación de un ensayo clínico que muestra los efectos beneficiosos de VASCAZEN® en la corrección de la...

Sep 10, 2014, 13:49 ET

Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients

WOODBRIDGE, ON, Sept. 10, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Sep 08, 2014, 11:50 ET

Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer

WOODBRIDGE, ON, Sept. 8, 2014  /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Sep 03, 2014, 17:55 ET

Los efectos únicos vasoprotectores y antihipertensivos de VASCAZEN® expuestos en ESC 2014

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" o la "Compañía"), una compañía farmacéutica especializada...

Sep 03, 2014, 14:19 ET

Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014

WOODBRIDGE, ON, Sept. 3, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...

Aug 27, 2014, 15:19 ET

Pivotal Therapeutics Announces Second Quarter Financial Results

WOODBRIDGE, ON, Aug. 27, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty...